Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial

BACKGROUND: Transmission blocking vaccines targeting the sexual-stages of the malaria parasite could play a major role to achieve elimination and eradication of malaria. The Plasmodium falciparum Pfs25 protein (Pfs25) is the most clinically advanced candidate sexual-stage antigen. IMX313, a compleme...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Immunol
Main Authors: de Graaf, Hans, Payne, Ruth O., Taylor, Iona, Miura, Kazutoyo, Long, Carol A., Elias, Sean C., Zaric, Marija, Minassian, Angela M., Silk, Sarah E., Li, Lee, Poulton, Ian D., Baker, Megan, Draper, Simon J., Gbesemete, Diane, Brendish, Nathan J., Martins, Filipa, Marini, Arianna, Mekhaiel, David, Edwards, Nick J., Roberts, Rachel, Vekemans, Johan, Moyle, Sarah, Faust, Saul N., Berrie, Eleanor, Lawrie, Alison M., Hill, Fergal, Hill, Adrian V. S., Biswas, Sumi
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2021
Assuntos:
Immunology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8318801/
https://ncbi.nlm.nih.gov/pubmed/34335606
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.694759
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados